Presentations and mechanisms of CNS disorders related to COVID-19

Marta Bodro, MD, PhD, Yaroslau Compta, MD, PhD, and Raquel Sánchez-Valle, MD, PhD

Neurol Neuroimmunol Neuroinflamm 2021;8:e923. doi:10.1212/NXI.0000000000000923

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the coronavirus disease 2019 (COVID-19) pandemic. In addition to severe respiratory symptoms, there are a growing number of reports showing a wide range of CNS complications in patients with COVID-19. Here, we review the literature on these complications, ranging from nonspecific symptoms to necrotizing encephalopathies, encephalitis, myelitis, encephalomyelitis, endotheliitis, and stroke. We postulate that there are several different mechanisms involved in COVID-19–associated CNS dysfunction, particularly activation of inflammatory and thrombotic pathways and, in a few patients, a direct viral effect on the endothelium and the parenchyma. Last, critically ill patients frequently present with protracted cognitive dysfunction in the setting of septic encephalopathy likely due to multifactorial mechanisms. Further studies are needed to clarify the relative contribution of each of these mechanisms, but available data suggest that CNS complications in COVID-19 are rare and probably not directly caused by the virus.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the coronavirus disease 2019 (COVID-19) pandemic, produces respiratory symptoms similar to those of SARS-CoV and Middle East respiratory syndrome coronavirus. The most dreadful complication is respiratory distress, with many patients requiring intensive care management. The viral infection activates inflammatory and prothrombotic pathways, which might be relevant for the pathogenesis of systemic and CNS symptoms.

Coronaviruses can also invade the CNS. In the case of SARS-CoV-2, trans-synaptic propagation from initial involvement of the olfactory epithelium and nerve is 1 proposed route. Accordingly, hyposmia and dysgeusia are common in COVID-19 and some studies suggest may associate with good prognosis. Alternatively, the virus might reach the CNS via the blood.

The frequency and types of neurologic complications in patients with COVID-19 are being elucidated. Initial studies showed that patients with mild cases of COVID-19 present with headache or dizziness, whereas those with severe disease can also develop an encephalopathy with agitation, confusion, impaired consciousness, seizures, and signs of corticospinal tract dysfunction. Ischemic stroke also occurs in COVID-19 and might be associated with a viral-related systemic prothrombotic state. Isolated cases with acute COVID-19–associated encephalitis have been reported, but demonstration of the presence of SARS-CoV-2 in the brain or CSF has been inconsistent.

In Spain, there have been at least 257,000 patients affected with COVID-19. The Albacete COVID-19 registry included 841 cases with neurologic symptoms, including 14 cases of ischemic or hemorrhagic stroke, totaling less than 2% of the series. Only 1 patient with encephalitis, 1 with optic neuritis, and 1 compatible with posterior reversible encephalopathy syndrome (likely related to hypertension) were recorded.

The aims of the present article are to review CNS complications associated with SARS-CoV-2 infection and analyze potential mechanisms of CNS damage.

**Literature search strategy**

We search PubMed for articles with clinical information on patients with CNS disorders related to SARS-CoV-2 infection. We excluded reports where CNS dysfunction was drug induced or could be explained by a nonspecific response to systemic infection, particularly in patients with preexisting structural lesions in the CNS. We also excluded (1) case reports on isolated cranial nerve (including hyposmia) or peripheral nervous system involvement (for this topic, see the recent review by Dalakas); (2) reviews and recommendations about treatment of preexisting neurologic disorders in the setting of COVID-19; and (3) studies on certain treatments used for neurologic diseases that could modify the risk or course of COVID-19.

**Overview of CNS complications of SARS-CoV-2**

Observational series have reported the presence of CNS symptoms in 31% to 69% of patients with severe COVID-19 vs 21% in patients with nonsevere COVID-19 (severity being established according to respiratory status). Dizziness (17%), headache (13%), impaired level of consciousness (8%), acute stroke (3%), ataxia (<1.0%), and seizures (<1.0%) were the main symptoms or syndromes reported in hospitalized patients. Agitation (69%), confusion (65%), signs of corticospinal tract dysfunction (67%), and impairment of executive functions (36%) were frequent symptoms in an observational series of 64 consecutive patients admitted to 2 intensive care units (ICUs) due to acute respiratory distress syndrome caused by COVID-19. In this series, at the time of hospital discharge, 33% of patients had a dysexecutive syndrome consisting of inattentiveness, disorientation, and poorly organized responses to commands.

In patients with COVID-19 admitted in the ICU with neurologic symptoms, the main MRI abnormalities include cortical FLAIR signal abnormalities and silent ischemic strokes. In one of these series, only 7 of the 58 patients (12%) underwent real-time PCR for SARS-CoV-2 in CSF, and all were negative. In the other series the patients who underwent EEG, only nonspecific changes were detected. A recent single case report of a patient with COVID-19 who needed extracorporeal membrane oxygenation (ECMO) had documented brain microbleeds as seen in other critical illness cases requiring ECMO and previously associated with influenza virus. The authors suggested an underlying endotheliopathy.

A retrospective multicenter case series from France showed that stroke, leptomeningeal enhancement, and encephalitis were the 3 most frequent neuroimaging findings among 64 patients with COVID-19. Confusion, impaired consciousness, agitation, corticospinal tract signs, and headache were...
the most common clinical features. Encephalitis occurred more frequently in younger patients, and agitation was associated with leptomeningeal enhancement.14

Finally, in a case series from the United Kingdom that included 43 patients with definitive (n = 29), probable (8), and possible (6) COVID-19, 5 categories of neurologic involvement emerged, with 3 specifically affecting the CNS: encephalopathies (n = 10); inflammatory CNS syndromes (n = 12) including encephalitis, acute disseminated encephalomyelitis (ADEM), and myelitis; and ischemic strokes (n = 8).15

Other than these series, well-characterized case reports with predominant CNS involvement other than stroke (reviewed separately) are scarce and are summarized in the table. In short, these include 14 cases, 9 of them (75%) were women, with age ranging from 24 to 69 years. Three were diagnosed with encephalitis, 4 with acute necrotizing encephalopathy, 2 with a clinicoradiologic picture compatible with endotheliitis (without pathologic confirmation), 2 with toxic-metabolic or vitamin deficiency–like encephalopathy, 2 with ADEM, and 1 with necrotizing myelitis.8,9,16–25 Of these 14 cases, only 3 had positive SARS-CoV-2 PCR in CSF (2 with negative nasopharyngeal swabs). In the remaining 10 cases, SARS-CoV-2 infection was demonstrated with nasopharyngeal PCR.

Acute necrotizing encephalopathy (n = 4)
The 4 cases reported so far with acute necrotizing encephalopathy resemble those seen after other viral infections, mainly influenza. All these cases had negative PCR for SARS-CoV-2 in CSF.19,22,25,26 Systemic inflammatory response syndrome (SIRS) and cytokine storm are also thought to underlie this condition. One of the patients also developed myocarditis.16,17 Two of the patients did not respond to treatment and died.16 An additional case without data on sex and age but with positive PCR in CSF and improvement with IV immunoglobulins (IVIgs) and plasma exchange has been reported.26

Encephalitis (n = 3)
The 3 reported cases with encephalitis differ in terms of clinical severity and CSF and MRI features.8,18 Thus, although all 3 showed CSF lymphocytic pleocytosis with increased protein concentration, 1 was severely ill, had positive PCR for SARS-CoV-2 in CSF, and showed structural lesions (mostly in the mesial right temporal lobe) on brain MRI.8 By contrast, the other 2 patients had rapid recovery, negative SARS-CoV-2 PCR for SARS-CoV-2, and normal MRI.18 Of interest, these 2 patients were the first reported cases in whom CSF levels of interleukins (ILs) and angiotensin-converting enzyme (ACE) were measured, showing increased levels of IL-1β (in both), IL-6 (in 1), and ACE (both).18 Accordingly, encephalitis of the former case might be related to direct CNS infection, whereas in the other 2, it could be linked to cytokine storm and endothelial inflammation as suggested by increased ILs and ACE levels in CSF.18

ADEM (n = 2) and acute necrotizing myelitis (n = 1)
ADEM is a clinicoradiologic condition that requires a multifocal CNS event of presumed inflammatory demyelinating cause, with an encephalopathic picture that cannot be explained by fever or other causes. It requires the presence on MRI of diffuse, poorly demarcated, large (>1–2 cm) lesions mostly involving the white matter, rarely with T1 hypointense white matter lesions.27 Deep gray nuclei (thalami and basal ganglia) lesions can be seen, without additional clinical and MRI findings in the ensuing 3 months. ADEM is not associated with aquaporin 4 (AQP4) antibodies, but up to 60% of patients have myelin oligodendrocyte glycoprotein (MOG) antibodies.

To the best of our knowledge, there are 2 single case reports of ADEM associated with COVID-19.9,21 One had positive SARS-CoV-2 PCR in CSF and a clinical picture that resembled neuromyelitis optica and was treated with IV methylprednisolone and IVIgs.10 The other patient had a negative PCR in CSF and developed decreased level of consciousness and impaired oculocephalic response after a stay in the ICU due to respiratory distress. Despite the diagnosis of ADEM, findings of spinal MRI were not reported. This patient was treated with IVIgs.21 Both patients had partial clinical and radiologic responses. A single case report of a patient with longitudinal extensive transverse necrotizing myelitis who again had a negative PCR for SARS-CoV-2 in CSF, was also negative for AQP4 and anti-MOG antibodies, and responded to methylprednisolone and plasmapheresis.25

Overall, in these 3 cases, the different evidence of the infectious status makes it difficult to infer the underlying pathophysiology. Although in 2 of the patients, the CSF PCR can potentially be considered a false-negative result, the clinical and radiologic features of these cases are suggestive of an inflammatory postinfectious process.

Endotheliitis-like involvement (n = 2)
The 2 reported cases of endotheliitis-like involvement include 1 patient with focal neurologic signs and the other with impaired level of consciousness. Both had marked perivascular enhancement on MRI, were negative for SARS-CoV-2 PCR in CSF, and had rapid clinical and radiologic recovery after treatment with IV methylprednisolone and plasma exchange, supporting the notion of an inflammatory mechanism.20,23 Although no pathologic studies were available, the MRI findings led to the diagnosis of endotheliitis. The inflammatory endothelial reaction might be related to cytokine storm or the ACE pathway, but neither of these mechanisms was studied in blood or CSF.

More recently, Pugin et al.28 reported 5 cases of COVID-19–related encephalopathy responsive to corticosteroids that the authors suggested were caused by endotheliitis based on the MR angiography features.
Table  Summary of published case reports of SARS-CoV-2–related CNS involvement other than stroke

<table>
<thead>
<tr>
<th>Diagnosis (proposed mechanism)</th>
<th>Case/s reported</th>
<th>Main clinical features</th>
<th>SARS-CoV-2 diagnosis</th>
<th>Laboratory tests</th>
<th>Imaging</th>
<th>Anti-inflammatory/ immunomodulatory treatment and outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute necrotizing encephalopathy (cytokine storm?)</td>
<td>F (late 50s) (Poyiadji et al.)&lt;sup&gt;16&lt;/sup&gt;</td>
<td>3 d of cough, fever, and altered mental status</td>
<td>+ Nasopharyngeal; − CSF</td>
<td>Blood: not mentioned; CSF: hemorrhagic (traumatic lumbar tap)</td>
<td>MRI bithalamic, medial temporal, and subinsular hemorrhagic lesions</td>
<td>IV immunoglobulin → admission to ICU due to SARS and the encephalopathy → final outcome undisclosed</td>
</tr>
<tr>
<td></td>
<td>F (59 y old) (Dixon et al.)&lt;sup&gt;22&lt;/sup&gt;</td>
<td>Cough, fever, dyspnea, and myalgia 10 d later → vacant staring, speech arrest, and seizures</td>
<td>+ Nasopharyngeal; − CSF undisclosed</td>
<td>Blood: lymphopenia; CSF: increased proteins and normal cell count</td>
<td>Chest X-ray: right basal consolidation; brain MRI: bithalamic, amygdala, striatal, and brainstem hemorrhagic lesions</td>
<td>No anti-inflammatory/ immunomodulatory treatment → death following withdrawal of ventilatory support (postmortem study declined)</td>
</tr>
<tr>
<td></td>
<td>F (33 y old) (Elkady et al.)&lt;sup&gt;15&lt;/sup&gt;</td>
<td>Fatigue, fever, and nasal congestion → generalized status epilepticus 4 d later</td>
<td>+ Nasopharyngeal; − CSF</td>
<td>Blood: increased IL-6 + CRP, troponin-1 + lymphopenia; CSF: lymphocytic pleocytosis and increased proteins</td>
<td>Echocardiography: 29% left ventricular ejection fraction; brain MRI: bilateral thalamic cerebellar hemorrhagic lesions</td>
<td>High-dose IV methylprednisolone → death</td>
</tr>
<tr>
<td></td>
<td>M (56 y old) (Morvan et al.)&lt;sup&gt;16&lt;/sup&gt;</td>
<td>Sudden loss of consciousness</td>
<td>+ Nasopharyngeal; − CSF</td>
<td>Blood: increased CRP, procalcitonin, and d-dimer</td>
<td>MRI: hypersignal of the thalamus, brainstem, and cerebellum with some hemorrhagic component</td>
<td>No anti-inflammatory treatment → ventricular derivation and mannitol → death</td>
</tr>
<tr>
<td>Encephalitis (directly viral or due to cytokine storm +/- ACE?)</td>
<td>M (24 y old) (Moriguchi et al.)&lt;sup&gt;8&lt;/sup&gt;</td>
<td>Headache and fatigue; day 9: loss of consciousness and seizure and neck stiffness</td>
<td>− Nasopharyngeal; + CSF</td>
<td>Negative (sic): lymphocytic pleocytosis; negative cultures and PCR for other bacteria and viruses</td>
<td>Chest CT: ground glass opacities; brain MRI: FLAIR mesial temporal hyperintensities</td>
<td>Steroids → still in the ICU due to pneumonia and impaired consciousness on publication</td>
</tr>
<tr>
<td></td>
<td>M (25 and 49 y old) (Bodro et al.)&lt;sup&gt;18&lt;/sup&gt;</td>
<td>Headache (both); left hemiparesis and diffuse rash (case 1); dyspnea and naming difficulties (case 2); progression to confusion, agitation (both)</td>
<td>+ Nasopharyngeal; − CSF</td>
<td>Blood: increased CRP, LDH, and d-dimer + mild lymphopenia (case 2); CSF: lymphocytic pleocytosis + increased proteins + increased IL-6 and ACE (both) and IL-1β (case 1)</td>
<td>Chest CT: normal (case 1) and bilateral peripheral opacities (case 2); brain MRI: normal (both)</td>
<td>No anti-inflammatory/ immunomodulatory treatment → quick recovery (48 and 72 h, respectively) with amnesia of the episode</td>
</tr>
<tr>
<td>Acute disseminated encephalomyelitis (directly viral or due to cytokine storm?)</td>
<td>F (64 y old) (Novi et al.)&lt;sup&gt;9&lt;/sup&gt;</td>
<td>Prior history of vitiligo and monoclonal gammopathy; Flu-like syndrome for 2 wk → anosmia-ageusia → bilateral optic neuritis and myelitis</td>
<td>+ Nasopharyngeal; − CSF; + serum anti-SARS-CoV-2 IgG</td>
<td>Blood: anti-AQ4 and anti-MOG: negative; CSF: lymphocytic pleocytosis + increased proteins</td>
<td>Brain MRI: multiple T1 post-Gd enhancing lesions of the brain including bilateral optic nerve enhancement; spinal MRI: a single T8 lesion</td>
<td>IV methylprednisolone 1 g/d × 5 d + IVig (2 g/kg in 5 d) → improvement of visual symptoms → follow-up brain MRI = partial improvement with a reduction in Gd-enhancing lesions</td>
</tr>
<tr>
<td></td>
<td>F (51 y old) (Parsons et al.)&lt;sup&gt;31&lt;/sup&gt;</td>
<td>Dyspnea, fever, and vomiting; → unresponsive with impaired oculocerebral response on sedation withdrawal (day 18)</td>
<td>+ Nasopharyngeal; − CSF</td>
<td>Blood: anti-AQ4 negative; CSF: xanthochromia</td>
<td>Brain MRI day 24: multifocal demyelinating lesions + intraventricular hemorrhage; brain MRI days 29-38-58: increase of lesions; spinal MRI: undisclosed</td>
<td>One course of IVig → improvement of consciousness, but left hemiparesis (day 36)</td>
</tr>
</tbody>
</table>

Continued
### Table Summary of published case reports of SARS-CoV-2–related CNS involvement other than stroke (continued)

<table>
<thead>
<tr>
<th>Diagnosis (proposed mechanism)</th>
<th>Case/s reported</th>
<th>Main clinical features</th>
<th>SARS-CoV-2 diagnosis</th>
<th>Laboratory tests</th>
<th>Imaging</th>
<th>Anti-inflammatory/immunomodulatory treatment and outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute necrotizing myelitis (cytokine storm?)</td>
<td>F (69 y old) (Sotoca et al.)25</td>
<td>Fever and dry cough for 8 d, followed by cervical pain, imbalance, and loss of strength and sensation in the left hand</td>
<td>+ Nasopharyngeal; − CSF</td>
<td>Blood: oligoclonal bands, anti-AQP4, anti-MOG, and antineuronal surface antibodies negative; CSF: mild lymphocytic pleocytosis + increased proteins</td>
<td>Brain MRI: normal; spinal MRI: T2 hyperintensity from the medulla oblongata to the C7 level with patchy enhancement; follow-up spinal MRI: caudal progression to T6 + central necrosis with peripheral enhancement at T1</td>
<td>Methylprednisolone 1g IV for 5 d → clinical worsening → plasmapheresis + oral prednisone 1 mg/kg × 5 d → eventual improvement</td>
</tr>
<tr>
<td>Endotheliitis-like involvement (cytokine storm? ACE?)</td>
<td>F (54 y old) (Brun et al.)23</td>
<td>Previous history of mild hypertension. Fever, dyspnea → altered mental status and right hemiparesis</td>
<td>+ Nasopharyngeal; − CSF (twice)</td>
<td>Blood: increased CRP, hyperferritinemia, and liver enzymes; CSF: hemorrhagic (traumatic lumbar tap)</td>
<td>Chest CT: ground glass opacities; brain MRI: restricted diffusion not enhancing supratentorial WM and bilateral pallidum</td>
<td>Steroids → after intubation and ICU stay, mild improvement of consciousness and right hemiparesis</td>
</tr>
<tr>
<td></td>
<td>F (44 y old.) (Pinto et al.)20</td>
<td>Minor respiratory symptoms for 7 d → right hand incoordination, word finding difficulties, and chest rash</td>
<td>+ Nasopharyngeal; − CSF</td>
<td>Blood: +anti-MOG antibodies; CSF: lymphocytic pleocytosis + increased proteins</td>
<td>Brain MRI: perivascular enhancement in the centrum semiovale bilaterally and left temporal and occipital ventricular horns</td>
<td>IV methylprednisolone + plasma exchange → rapid clinical and radiologic recovery</td>
</tr>
<tr>
<td>Toxic/Wernicke like encephalopathy (inflammation? hypoxia?)</td>
<td>F (60 and 35 y old) (Pascual-Goni et al.)24</td>
<td>Case 1: fever, hyponxia, and cough for 10 d → diplopia; hypoxemia (PaO2, 67 mm Hg) without dyspnea; case 2: vomiting (prior history of bulimia) for 3 wk → progressive encephalopathy, with hypoxemia (PaO2, 61 mm Hg)</td>
<td>+ Nasopharyngeal; − CSF</td>
<td>Blood: lymphopenia and increased CRP; thiamine, pyridoxine normal (both); CSF: normal proteins and cell count but increased LDH (both)</td>
<td>Brain MRI: FLAIR hyperintense lesions in the brainstem, including the VI cranial nerve nuclei, thalami, medial temporal lobes, mammillary bodies, and hypothalamus (similar in both)</td>
<td>No specific anti-inflammatory or immunomodulatory treatments; thiamine and pyridoxine supplementation despite normal vitamin levels in case 2 → persistence of diplopia on discharge in case 1 and partial recovery in case 2</td>
</tr>
</tbody>
</table>

**Abbreviations:** ACE = angiotensin-converting enzyme; AQP4 = aquaporin 4; CRP = C-reactive protein; FLAIR = fluid-attenuated inversion recovery; ICU = intensive care unit; IL = interleukin; IVIg = IV immunoglobulin; LDH = lactate dehydrogenase; MOG = myelin oligodendrocyte glycoprotein; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

---

**Toxic/Wernicke-like encephalopathy (n = 2)**

Two patients were identified at a single institution with COVID-19 who had developed clinical and brain MRI features that resembled Wernicke encephalopathy, prompting supplementation of vitamins despite having normal blood levels.24 The patients showed partial improvement. The authors considered the symptoms as related to SARS-CoV-2, either by direct viral involvement or secondary to the systemic inflammatory response to the virus.

**Stroke**

In a series of 388 patients, thromboembolic events occurred in 28 patients (8%) including 9 cases with ischemic stroke (2.5%).29 Likewise, in a study of ischemic events in critically ill patients with COVID-19, 28 of 184 cases had thrombotic events (15%), including 3 with stroke.30 In another series of 1,683 COVID-19 cases, 23 (1.4%) developed cerebrovascular disease.31 Cerebral and chest CT scans were performed in all cases and MRI in 6, with histologic samples available for 6/23 cases (2 brain biopsies and 4 arterial thrombi). Cerebral ischemia occurred in 17 cases (74%), including 2 cases with arterial dissection (9%), whereas intracerebral hemorrhage happened in 5 (22%), and 1 (4%) had posterior reversible encephalopathy. Ischemic strokes were frequent in the vertebrobasilar territory. In the hemorrhagic group, subarachnoid hemorrhage, parieto-occipital leukoencephalopathy, microbleeds, and single or multiple focal hematomas were characteristic. Brain biopsies showed thrombotic microangiopathy and endothelial injury, with no evidence of vasculitis or
necrotizing encephalitis. Outcome was poor, 8 died, and 17 had a median Rankin scale score of 4–6 at hospital discharge.31

In another study, Al Saiegh et al. reported 2 patients with cerebrovascular disease in the setting of COVID-19. One was a 31-year-old man with a Hunt & Hess grade 3 subarachnoid hemorrhage and the other a 62-year-old woman with ischemic stroke with massive hemorrhagic transformation.32 Oxley et al. reported 5 patients with COVID-19 younger than 50 years with large vessel ischemic stroke,33 and Gonzalez-Pinto et al.34 described a 36-year-old man with malignant ischemic stroke of the middle cerebral artery and a free-floating thrombus in the ascending aorta. Overall, these reports suggest that stroke is more frequent than expected in patients with COVID-19 younger than 50 years.

**Other CNS involvement**

There are other case reports difficult to classify. For example, M´endez-Guerrero et al. described a 50-year-old man presenting with a hypokinetic syndrome, hyposmia, opsoclonus, and myoclonus after a severe COVID-19 infection with positive nasopharyngeal but negative CSF PCR. The MRI was normal, but there was impaired presynaptic dopamine imaging. The patient spontaneously recovered.35 In another report, Rabano-Suarez and colleagues33,36 described 3 cases (2 men, 63 and 76 years and a woman of 88 years) with COVID-19 who had generalized myoclonus with normal CSF, imaging (MRI or CT), and EEG. They slowly improved with either corticosteroids or plasma exchange, leading the authors to conclude that the myoclonus was postinfectious and immune mediated.

**Mechanisms of CNS damage associated with SARS-CoV-2**

**Direct viral injury**

Like other well-recognized neuroinvasive human viruses, coronavirus might invade the CNS, via trans-synaptic propagation from the olfactory epithelium or through systemic circulation, entering the CNS using the endothelial ACE2 receptors expressed in brain vessels, or crossing a leaky blood-brain barrier affected by systemically produced cytokines (figure).37

Therefore, SARS-CoV-2 might reach the CNS by different routes and induce short-term illnesses, such as viral encephalitis. On the other hand, SARS-CoV-2 might persist in resident cells of the CNS and be involved in long-term neurologic sequelae in genetically or otherwise predisposed individuals.37

There are case reports of the detection of human coronavirus OC43 RNA in brain biopsies by metagenomic sequencing in immunosuppressed children with encephalitis.38,39 Moreover, SARS-CoV-1 has also been detected at autopsy in brain tissue of patients with SARS.40–42 However, as previously indicated, there are limited data suggesting the presence of SARS-CoV-2 in the CNS of patients with COVID-19. In an autopsy series of patients with COVID-19 without neurologic symptoms, SARS-CoV-2 was detected in the brain of 8 (38%) of 21 patients with low levels of SARS-CoV-2 copies per cell.43 In another autopsy study of 10 patients,44 no signs of encephalitis or CNS vasculitis were found, and the PCR in CSF was negative.

Only 2 of the 11 patients who underwent PCR testing in CSF (table) were positive (1 case of encephalitis and 1 ADEM), suggesting that the virus can directly invade the nervous system in some cases.8,9

**Neuronal pathway**

Some human coronaviruses such as HCO-OC43, HCOV-229E, and SARS-CoV-1 can be considered neurotropic viruses due to their capacity to invade the CNS via the neuronal pathway.5,37,45 Viruses can migrate by infecting sensory or motor nerve endings, achieving retrograde or anterograde neuronal transport through kinesins, dynein, and motor proteins.46 Experimental intranasal coronavirus infection in susceptible mice shows that once the virus has invaded the CNS through the olfactory route, it can disseminate to several regions of the brain and brainstem before eventually reaching the spinal cord.45,47

**Blood circulation pathway**

Viruses can enter the CNS without infecting neurons. Some viruses, such as HIV, infect leukocytes and may infiltrate the brain parenchyma. This Trojan horse mechanism is facilitated by the fact that the infected cells are naturally able to cross the blood-brain barrier.48 Alternatively, other viruses such as Japanese encephalitis virus are released into the blood and increase the permeability of the blood-brain barrier through increased production of proinflammatory cytokines that facilitate entry into the CNS.39 This mechanism may be plausible for SARS-CoV-2 due to the severe systemic inflammation with elevated cytokine levels that can constitute a link between direct CNS infection and CNS damage due to systemic and intrathecal cytokine storm.50 Alternatively, expression of ACE2 receptors in the endothelium of brain blood vessels provides an additional entry route for SARS-CoV-2 that can be linked with endotheliitis and inflammatory injury of the CNS (see below).51 Further studies analyzing how SARS-CoV-2 invades the CNS are warranted.

**Inflammatory-mediated injury**

**Cytokine storm**

COVID-19 has caused a large number of fatalities, most due to multiple organ failure secondary to the virus-induced SIRS or SIRS-like immune disorders.52 Accumulating evidence suggests that patients with severe COVID-19 might have a cytokine storm syndrome characterized by increased IL-1, IL-2, IL-6, granulocyte-colony stimulating factor, interferon-γ inducible protein 10, macrophage inflammatory protein 1α, and tumor necrosis factor (TNF)-α.53 Lung tissue from
patients with SARS related to coronavirus showed hemo-
phagocytosis, which is a central pathologic feature of cytokine
storm. Patients with SARS also exhibited high levels of in-
terferon-γ and IL-18, which are particularly important in the
cytokine storm syndrome. Thus, the host’s immune re-
response and development of inflammation in the lung likely
plays an important role in COVID-19.

Li et al. found that coronavirus neurovirulence correlates
with the ability of the virus to induce proinflammatory cyto-
kine (IL-12 p40, TNFα, IL-6, IL-15, and IL-1β) signaling from
astrocytes and microglia in a mouse model. Other investiga-
tors also showed that primary glial cell cultures exposed to
coronavirus secrete the proinflammatory cytokines IL-6, IL-
12, IL-15, and TNFα.

In cases of acute necrotizing encephalopathy, acute nec-
rotizing myelopathy, encephalitis, and ADEM with nega-
tive PCR in CSF, cytokine storm is the most probable
mechanism of CNS dysfunction. A recent single autopsy
case report described a combination of hemorrhagic white
matter lesions with areas of necrosis and organizing mi-
croscopic infarcts, along with perivascular ADEM-like al-
terations, suggesting a combination of vascular and
inflammatory injury.

The hyperinflammatory response that leads to SIRS can manifest
with high levels of C-reactive protein, coagulopathy (elevated D-
dimer levels, low platelet count, and fibrinogen levels), tissue
damage (elevated LDH and alanine aminotransferase and aspar-
tate aminotransferase levels), macrophage/hepatocyte activation
(elevated ferritin levels), and cytopenias (thrombocytopenia and
lymphopenia). Therefore, early anti-inflammatory intervention
such as anticytokine therapies could reduce the risk of injury in the
nervous system. Glucocorticoids remain the first treatment
option, and clinical trials are urgently needed to test their efficacy
and identify optimal dosing, especially given the clear advantage of
glucocorticoids in worldwide availability and cost.

**Endotheliitis**

The binding of SARS-CoV-2 to the ACE2 receptor may cause
or worsen high blood pressure, increasing the risk of cerebral
hemorrhage. Moreover, the interaction of the SARS-CoV-2
spike protein with ACE2 receptors expressed in the capillary
endothelium of brain blood vessels may lead to injury of the
blood-brain barrier. This could explain the increased risk of
ischemic stroke (see below) accompanied by perivascular
inflammation suggestive of endotheliitis.

**Thrombotic injury**

Increased levels of circulating prothrombotic factors have
been reported in patients with severe COVID-19, reflecting a
hypercoagulable state. Proinflammatory cytokines can in-
duce endothelial and mononuclear cell activation with ex-
pression of tissue factor leading to activation of the
coagulation cascade and thrombin generation. Circulation of
free thrombin can activate platelets and lead to thrombosis. It
has been postulated that the binding of SARS-CoV-2 to the
ACE2 receptor causes an imbalance of the renin angiotensin
system favoring the ACE1-angiotensin axis and contribut-
ing to endothelial dysfunction, organ damage, and clot
formation.
Hypoxia-mediated injury and encephalopathy of the critically ill

The diffuse alveolar and interstitial inflammatory edema in COVID-19 leads to impairment of alveolar gas exchange and CNS hypoxia. Anerobic metabolism in the mitochondria of brain cells results in acidosis, vasodilatation, increased interstitial edema, obstruction of cerebral blood flow, intracranial hypertension, and coma.

Between 5%\(^1,2\) and 14%\(^3\) of patients with COVID-19 require admission to the ICU. A high number of patients in the ICU develop symptoms of acute cerebral dysfunction described as delirium, acute confusional state, acute brain failure, organic brain syndrome, acute organic reaction, cerebral insufficiency, and ICU psychosis and grouped under the term “encephalopathy of the critically ill” or “critical illness brain syndrome.” This encephalopathy is an independent predictor of mortality and is associated with long-term cognitive dysfunction.\(^4\) The mechanisms underlying this encephalopathy are heterogeneous and multifactorial, including direct brain injury, respiratory, heart, renal or liver failure, sepsis, endocrine or electrolyte imbalance, and pharmacologic agents.\(^5\)

In a series of 18 patients with COVID-19 who died in the ICU and underwent autopsy, acute hypoxic ischemic damage was identified in all. Nevertheless, the clinical description is very limited, and none of the cases underwent MRI, EEG, or CSF examination.

Conclusions

CNS involvement in COVID-19 appears to be protean both in its clinical presentations and underlying mechanisms. Direct viral infection of the CNS has been demonstrated in a few cases. In most patients with nonsevere forms of the disease (according to the respiratory status), inflammatory or cerebrovascular mechanisms appear to be the predominant CNS complications. In this context, the involved mechanisms include inflammatory (cytokine storm), prothrombotic, and endothelial (via ACE2) pathways. In critically ill patients with COVID-19, additional mechanisms include those typically related to encephalopathy of the critically ill, such as hypoxia, systemic disturbances, and drugs, among others.

Nevertheless, the number of patients with specific syndromes (encephalitis, ADEM, myelitis, and endotheliitis) is small, suggesting that the frequency of these complications is rare, making difficult an accurate classification. There are limited data to determine whether hypoxemic or post-ICU or septic encephalopathy is more frequent or severe in COVID-19 than in other respiratory infections that are similarly severe. Moreover, there is a need for more reliable and standardized biomarkers for infection of the CNS (PCR and antibodies against SARS-CoV-2 in CSF) and for the involvement of endothelial, inflammatory, and prothrombotic pathways within the CNS.

Last but not least, treatment strategies for these potential pathophysiologic pathways are limited. The usefulness of immunomodulatory treatments (corticosteroids and plasma exchange), anti-IL antibodies (tocilizumab and anakinra), full-dose anticoagulants, and others needs to be investigated and established.

In summary, both parenchymal (encephalitis, myelitis, or combination of both) and vascular (endotheliitis) CNS inflammatory responses along with an increased risk of hemorrhagic and ischemic stroke have been described as complications of COVID-19. However, severe CNS complications associated with COVID-19 are rare and probably not directly caused by the virus in most cases. Severe cases of COVID-19 frequently manifest as a syndrome that overlaps with encephalopathy of the critically ill, whereas fewer cases (at least to date) present with specific CNS syndromes. Further studies are needed to clarify the pathogenesis and long-term prognosis of CNS involvement in patients with COVID-19.

Acknowledgment

To people suffering from the COVID-19 pandemic and the health professionals involved in their care and the handling of this unprecedented global crisis. The authors are also most grateful to Prof. Francesc Graus for advice and review of the manuscript.

Study funding

No targeted funding reported.

Disclosure

The authors have no relevant disclosures. Go to Neurology.org/NN for full disclosures.

Publication history


Appendix

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marta Bodro,</td>
<td>Hospital Clinic de</td>
<td>Main contributor</td>
</tr>
<tr>
<td>MD, PhD</td>
<td>Barcelona, Spain</td>
<td></td>
</tr>
<tr>
<td>Yaroslau Compta,</td>
<td>Hospital Clinic de</td>
<td>Main contributor</td>
</tr>
<tr>
<td>MD, PhD</td>
<td>Barcelona, Spain</td>
<td></td>
</tr>
<tr>
<td>Raquel Sánchez-Valle,</td>
<td>Hospital Clinic de</td>
<td>Main contributor</td>
</tr>
<tr>
<td>MD, PhD</td>
<td>Barcelona, Spain</td>
<td></td>
</tr>
</tbody>
</table>

References


Presentations and mechanisms of CNS disorders related to COVID-19
Marta Bodro, Yaroslau Compta and Raquel Sánchez-Valle
Neurol Neuroimmunol Neuroinflamm 2021;8;
DOI 10.1212/NXI.0000000000000923

This information is current as of December 11, 2020

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/8/1/e923.full.html

References
This article cites 64 articles, 13 of which you can access for free at:
http://nn.neurology.org/content/8/1/e923.full.html#ref-list-1

Citations
This article has been cited by 2 HighWire-hosted articles:
http://nn.neurology.org/content/8/1/e923.full.html#otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
COVID-19
http://nn.neurology.org/cgi/collection/covid_19
Encephalitis
http://nn.neurology.org/cgi/collection/encephalitis
Other cerebrovascular disease/ Stroke
http://nn.neurology.org/cgi/collection/other_cerebrovascular_disease_stroke

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.